ODM-201
- CAS No.
- 1297538-32-9
- Chemical Name:
- ODM-201
- Synonyms
- Darolutamide;BAY-1841788;0DM021;ODM 021;ODM-201;CS-1565;ODM-021;Darolutamid;Darrolumide;Darolutamide D4
- CBNumber:
- CB43052901
- Molecular Formula:
- C19H19ClN6O2
- Molecular Weight:
- 398.85
- MOL File:
- 1297538-32-9.mol
- Modify Date:
- 2024/3/27 16:59:26
SAFETY
Risk and Safety Statements
Symbol(GHS) | GHS07,GHS09 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Signal word | Warning | |||||||||
Hazard statements | H410-H302-H400 | |||||||||
Precautionary statements | P264-P270-P301+P312-P330-P501-P273-P391-P501-P273-P391-P501 | |||||||||
NFPA 704 |
|
ODM-201 Chemical Properties,Uses,Production
Description
ODM-201 is a novel androgen receptor (AR) inhibit designed to inhibit the growth of prostate cancer cells through binding to the AR to inhibit the testosterone-induced AR nuclear translocation. It is particularly used in patients with progressive metastatic castration-resistant prostate cancer. It is effective in inhibiting the activity of some mutant ARs emerging during antiandrogen therapies, including the F876L mutation version which is resistant to enzalutamide and ARN-509 (the second-generation antiandrogens).Therefore, it has potential to overcome the resistance issue occurring upon AR-targeted therapies.
Uses
ODM-201 is a compound being used as a novel next-generation androgen receptor-directed therapy for prostate cancer.
References
Moilanen, Anu Maarit, et al. "Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies." Sci Rep 5.2(2015):12007. Fizazi, Karim, et al. "ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data." Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of 2013. Fizazi, K, et al. "Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial." Lancet Oncology 5.9(2014):975-85.
ODM-201 Preparation Products And Raw materials
Raw materials
1of2
chevron_rightPreparation Products
Supplier | Tel | Country | ProdList | Advantage | Inquiry |
---|---|---|---|---|---|
Venkatasai Life Sciences | +91-9908134868 +91-8008303069 | Hyderabad, India | 186 | 58 | Inquiry |
Vijaya Pharma And Life Science | +91-8939866271 +91-8939866271 | Tamil Nadu, India | 320 | 58 | Inquiry |
CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
Pharma Affiliates | 172-5066494 | Haryana, India | 6761 | 58 | Inquiry |
Henan Bao Enluo International TradeCo.,LTD | +86-17331933971 +86-17331933971 | China | 2503 | 58 | Inquiry |
Hebei Kangcang new material Technology Co., LTD | +8615713292910 | China | 341 | 58 | Inquiry |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | China | 21669 | 55 | Inquiry |
Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 | China | 9337 | 55 | Inquiry |
Related articles
- The introduction of Darolutamide (ODM-201)
- Darolutamide (ODM-201) is a structurally distinct non-steroidal androgen receptor (AR) antagonist being developed by Orion and....
- Jan 17,2024
- Preparation of ODM-201
- ODM-201 is a new generation AR inhibitor with superior preclinical efficacy compared to enzalutamide and bicalutamide, it does....
- Nov 12,2019